Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.18 |
| Open | 8.17 |
| 1-Year Change | 94.99% |
| Day's Range | 8.17 - 8.4 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 8.18 | 0.30 | 3.81% | 7.88 | 8.19 | 7.87 |
| Apr 23, 2025 | 7.92 | 0.07 | 0.89% | 7.85 | 8.14 | 7.85 |
| Apr 22, 2025 | 7.79 | 0.24 | 3.18% | 7.55 | 7.94 | 7.49 |
| Apr 21, 2025 | 7.50 | 0.23 | 3.16% | 7.27 | 7.72 | 7.20 |
| Apr 17, 2025 | 7.37 | 0.28 | 3.95% | 7.09 | 7.47 | 7.09 |
| Apr 16, 2025 | 7.19 | -0.13 | -1.78% | 7.32 | 7.34 | 7.05 |
| Apr 15, 2025 | 7.37 | 0.43 | 6.20% | 6.94 | 7.37 | 6.94 |
| Apr 14, 2025 | 7.00 | 0.16 | 2.34% | 6.84 | 7.03 | 6.77 |
| Apr 11, 2025 | 6.78 | 0.51 | 8.13% | 6.27 | 6.81 | 6.27 |
| Apr 10, 2025 | 6.38 | -0.16 | -2.45% | 6.54 | 6.54 | 5.98 |
| Apr 9, 2025 | 6.73 | 0.50 | 8.03% | 6.23 | 7.01 | 6.09 |
| Apr 8, 2025 | 6.44 | -0.55 | -7.87% | 6.99 | 7.00 | 6.33 |
| Apr 7, 2025 | 6.75 | 0.22 | 3.37% | 6.53 | 7.01 | 6.39 |
| Apr 4, 2025 | 6.79 | -0.29 | -4.10% | 7.08 | 7.14 | 6.74 |
| Apr 3, 2025 | 7.29 | 0.06 | 0.83% | 7.23 | 7.38 | 7.12 |
| Apr 2, 2025 | 7.39 | 0.24 | 3.36% | 7.15 | 7.40 | 7.14 |
| Apr 1, 2025 | 7.21 | -0.23 | -3.09% | 7.44 | 7.45 | 7.19 |
| Mar 31, 2025 | 7.47 | -0.19 | -2.48% | 7.66 | 7.66 | 7.43 |
| Mar 28, 2025 | 7.83 | 0.05 | 0.64% | 7.78 | 7.89 | 7.65 |
| Mar 27, 2025 | 7.79 | 0.01 | 0.13% | 7.78 | 7.85 | 7.72 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
| Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com